⚠ Educational reference only — not medical advice.** This article is for research and educational reference. Always consult your own physician before considering any peptide protocol. See the full Disclaimer at the end of this article.

Introduction
GHRP-2 (pralmorelin) is a synthetic hexapeptide growth-hormone-releasing peptide developed in the 1990s. Member of the broader GH-secretagogue class. Used as a diagnostic GH-stimulation agent in some countries; not approved as a therapeutic in the United States.

Mechanism of Action
Agonist at the growth-hormone-secretagogue receptor (GHS-R1a), the endogenous receptor for ghrelin. Receptor activation drives pulsatile GH release from somatotrophs and synergizes with endogenous GHRH. Co-administration with a GHRH or GHRH-analogue (e.g., sermorelin, CJC-1295) produces additive GH release in research protocols.

Research Indications
GH-deficiency diagnostics, adult sarcopenia, cachexia adjunct, and recovery-oriented protocols. Not a substitute for recombinant human GH where indicated.

Reconstitution
Typical 5 mg lyophilized vial: add **2 mL of bacteriostatic water**, swirl gently. Final concentration **2500 mcg/mL (2.5 mg/mL)** — each 0.04 mL (4 units on a U-100 insulin syringe) delivers 100 mcg.

Dosing Protocol (research literature)
Research protocols typically dose **100–300 mcg subcutaneously 1–3 times daily**, with the largest pulse pre-sleep to align with endogenous GH rhythm. **Frequent pairing**: GHRP-2 + sermorelin or CJC-1295 (no DAC), each at 100 mcg, pre-sleep on empty stomach. Cycle length **8–12 weeks** with **4-week off** before re-cycling.

Administration
Subcutaneous into abdominal fat, rotating sites. Dose on an empty stomach (food blunts the GH pulse). Pre-sleep dose 60–90 minutes after last food/drink other than water.

Storage & Handling
Lyophilized: refrigerate (2–8°C). Reconstituted: refrigerate; stable approximately **21–28 days**. Protect from light.

Side Effects
Transient: flushing, mild injection-site reaction, hunger (less pronounced than GHRP-6). Documented modest transient elevations in cortisol and prolactin.

Contraindications
Active malignancy, untreated proliferative diabetic retinopathy, pregnancy, lactation, uncontrolled diabetes.

Monitoring
Baseline IGF-1, fasting glucose, HbA1c, lipid panel. Re-measure IGF-1 at 6–8 weeks; trough IGF-1 above the age-adjusted reference range warrants dose reduction. Counsel on carpal-tunnel symptoms, peripheral edema, and arthralgia at higher exposures.

Disclaimer
**This article is for informational and research-reference purposes only.** Nothing in this document constitutes medical advice, a prescription, or a recommendation from a physician. The reconstitution, dosing, and protocol information above reflects ranges commonly cited in published research and clinician-directed protocols — it is provided as reference material only, not as instructions, an endorsement of off-label use, or a substitute for individualized medical evaluation.

**Customers should do their own research and consult their own physician** before considering any peptide protocol. Whether a given compound is appropriate for an individual — and at what dose, for what duration, and alongside what monitoring — is a decision that only a licensed clinician with knowledge of that individual’s medical history, current medications, and conditions can make.